Atlanta, Georgia · Biopharma Intelligence · Doctoral Research · Mentoring

I help people make hard decisions with better evidence.

I'm Puru Gaur: a Director of Competitive Intelligence at a leading life sciences advisory firm, a Doctor of Business Administration in Health candidate at University College London — ranked #9 in the world in the QS World University Rankings 2026. This site is my hub: the work, the research, and the mentoring.

  • 10 years in biopharma and health policy
  • Georgia State B.S. in Public Health
  • Emory MPH
  • Arizona MBA
  • Doctor of Business Administration in Health candidate, University College London (#9 in the world)
  • Volunteer instructor and mentor since 2015
The Person

Meet Puru Gaur.

Portrait of Puru Gaur with the Atlanta skyline behind him
Puru Gaur · Atlanta, Georgia

I'm an Atlanta-based biopharma intelligence leader. I turn deals, data, and regulatory chess moves into decisions people can act on.

My career spans Biogen, PhRMA, AmerisourceBergen (now Cencora), EVERSANA, and Vir Biotechnology. Today, I'm a Director of Competitive Intelligence at a leading life sciences advisory firm, where I advise clients across the spectrum — from multi-billion-dollar pharmaceutical companies to smaller biotechs.

I hold an MPH in Health Policy and Management from Emory University, home of the Rollins School of Public Health, ranked #2 in the nation by U.S. News & World Report, and an MBA in Healthcare Management from the University of Arizona, ranked #7 in the nation by U.S. News & World Report.

My path in public health began at Georgia State University, where I earned a Bachelor of Science in Public Health from the School of Public Health — ranked #1 in Georgia for public health by U.S. News & World Report.

I'm now a Doctor of Business Administration in Health candidate at the Global Business School for Health, University College London — ranked #9 in the world in the QS World University Rankings 2026.

My doctoral research asks a practical question: how do health systems pay for one-time curative therapies when the payment system was built for chronic care? I'm studying outcomes-based financing — spreading the cost over time and tying payment to whether the therapy delivers the result it promises — beginning with advanced therapies for vision restoration. One of my starting points is the 2008 mortgage crisis — a floor, not a ceiling, for how pooled financing should be built. Read the research →

Beyond the desk, I volunteer as a Taekwondo instructor for children in under-resourced neighbourhoods and serve as a public-health advisor with Ladybug for Girls®. Ladybug for Girls® Sport Wellness is an American sports-based youth development program that provides girls ages 5-12 years with evidence-based health education classes and sport safety resources. The principle is simple: plant trees under whose shade you do not expect to sit.

Based inAtlanta, Georgia
Experience10 years across biopharma and health policy
EducationGeorgia State University B.S. in Public Health · Emory MPH · University of Arizona MBA
Doctoral researchFinancing curative therapies — University College London
ServiceVolunteer instructor and mentor since 2015
Read the full bio → View résumé →
Doctoral Research

Paying for cures, honestly.

A one-time cell or gene therapy can deliver decades of benefit, but the bill arrives on day one — and the savings land with everyone except the payer who wrote the cheque: patients, families, employers, and public programs. My doctoral research at University College London — ranked #9 in the world — asks how health systems close that gap.

My starting point is the 2008 mortgage crisis. Structured finance didn't fail because pooling risk is a bad idea; it failed on misaligned incentives, weak underwriting, mispriced risk, and pools nobody could see inside. Treat 2008 as the floor, not the ceiling — the minimum lessons a new structure has to beat, not the limit of what's possible.

So the work tests a structure built to beat that floor: payments tied to independently verified outcomes, risk pooled honestly across patients and payers, transparent terms, and stress tests for the bad years — starting with therapies that restore vision, where the return shows up as independence and work, not just sight.

Read the research →
Beyond the Desk

Quality control has paws.

Momo, a Golden Retriever, brings the enthusiasm. Leo, a German Shepherd, brings the standards. Together they review the household's important decisions daily — walks, snacks, and whether a plan is actually ready.

Meet Momo & Leo →
Momo, a Golden Retriever
Momo · Chief Enthusiasm Officer
Leo, a German Shepherd
Leo · Head of Standards

Working on a hard decision? Let's talk.

Contact Puru →